Allergan CEO vows to limit exorbitant drug price increases

7 September 2016
allergan-new-big

The chief executive of Ireland-headquartered Allergan (NYSE: AGN) has vowed to limit price increases of its medicines and said it will not engage in ‘price gouging actions’ or ‘predatory pricing’.

In a blog post on the company’s website, Brent Saunders, condemned those ‘outliers’ who have imposed dramatic price increases on their products, accusing them of violating their social contract with patients.

He insisted that Allergan had made a formal commitment, as part of a 'social contract' to abide by ‘responsible pricing ideals’ and called on other companies in the industry to do the same.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical